乳がん治療薬の世界市場:モノクローナル抗体、ホルモン、化学療法、キナーゼ阻害剤、その他

◆英語タイトル:Breast Cancer Drugs Market 2016-2026 : Revenue Forecasts for Monoclonal Antibodies, Hormones, Chemotherapy, Kinase Inhibitors and Other Pharmaceuticals
◆商品コード:VGAIN6041534
◆発行会社(調査会社):visiongain
◆発行日:2016年3月
◆ページ数:174
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名利用)GBP1,999 ⇒換算¥295,852見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥443,852見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥739,852見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。

販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Breast Cancer Therapies – Discover From 2016 What Revenues Are PossibleAre you interested in the breast cancer drug market’s future? If so, you find that sales forecasting from 2016 in our new report. See there what is possible for those products and companies. You also explore trends, results and R&D, discovering opportunities and prospects.

Visiongain’s study gives revenue predictions to 2026 at overall world market, submarket, product and national level. Avoid falling behind in data or losing influence. Instead discover what progress, opportunities and revenues those anti cancer drugs can achieve. See what is possible in that leading drugs market.

Please read on now to explore that industry and see what future revenue its expanding market could generate.

Original analysis to benefit your research, plans, decisions and proposals
The future holds great potential for pharma companies treating breast cancer. New products enter that market and novel drug candidates reach late-stage clinical testing. Discover, from 2016, revenues and other progress that are possible.

Besides revenue forecasting to 2026, our new work shows you recent results, sales growth rates and market shares. You assess research and development too. And in that report you gain 93 tables, 49 charts and interviews with two companies.

Our study’s purpose is to help your research, analyses and decisions on breast cancer treatments, benefiting your authority and reputation for commercial insight. That way you can stay ahead in knowledge to help you stand out and succeed.

Although no single report covers everything, the following sections show how our new investigation benefits your work.

Forecasts covering the overall world market and segments for treating breast cancer
Discover in our new analysis revenue predictions to 2026 for breast cancer submarkets at world level. See what is possible for these four therapeutic classes:
• Monoclonal antibodies (mAbs)
• Chemotherapy and hormone therapy
• Kinase inhibitors
• Other medicines.

Where lie the best sales potentials? With our survey you assess outlooks for revenue expansion, seeing where you can gain. Also investigate competitors’ actions and outlooks. Discover, from 2016, what is possible.

With a rising incidence of breast cancer worldwide and large patient populations, the demand for better treatments will continue to bolster that industry and market. Explore prospects for patients, healthcare providers and pharma companies.

Our new investigation also shows you revenue predications by product, exploring how those agents can succeed.

Forecasts for leading drugs – what sales are possible?
How will individual breast cancer medicines perform from 2016 to 2026 at world level? Our study forecasts revenues of these nine leading brands:
• Herceptin (trastuzumab), Roche
• Perjeta (pertuzumab), Roche
• Afinitor (everolimus), Novartis
• Faslodex (fulvestrant), AstraZeneca
• Ibrance (palbociclib), Pfizer
• Avastin (bevacizumab), Roche
• Kadcyla (ado-trastuzumab emtansine), Roche
• Femara (letrozole), Novartis
• Abraxane (paclitaxel Protein-Bound), Celgene

Our investigation also forecasts sales of two biosimilar drug classes: trastuzumab and bevacizumab.

In that study you see how high revenues can go, finding products and years with highest predicted sales. You also examine competition. That way you investigate what is happening, understanding challenges, trends, competitors and opportunities.

Discover what the future holds for treating breast cancer. Our work also shows you geographical sales predictions.

National markets – what outlooks for those anticancer drug revenues?
Advances in the biopharma industry expand the range and use of medicines to treat breast cancer in developed and developing countries. Our work shows you individual revenue forecasts to 2026 for 11 leading national markets:
• The United States
• Japan
• Germany, France, Italy, the United Kingdom and Spain (EU5 countries)
• Brazil, Russia, India and China (BRIC group)

With our study you assess regions with highest revenues and potential sales growth. Explore outlooks for treating breast cancers, including discussions of patients’ and healthcare providers’ needs.

You also examine developments leading to novel and improved breast cancer medications.

R&D for those anticancer medicines – trends, innovations and progress
In our study you investigate research and development on breast cancer. You examine advances in oncology, assessing clinical trials and seeing what they show.

Our survey discusses 18 medicines in development for breast cancer, including these agents:
• Taselisib (GDC-0032/RG7604), Roche
• Atezolizumab (MPDL3280A/RG7446), Roche
• Buparlisib (BKM120), Novartis
• Alpelisib (BYL719), Novartis
• Ribociclib (LEE011), Novartis
• AZD5363, AstraZeneca
• MEDI-573, AstraZeneca and MedImmune
• Abemaciclib (LY2835219), Eli Lilly
• Veliparib (ABT-888), AbbVie.

Our work shows you what is possible. R&D gains momentum from rising disease prevalence and other forces making treatments for that common cancer more widely used. See how demand increases.

Events and changes affecting companies treating breast cancer
Our study explains forces shaping the industry and market, letting you explore what is happening from 2016:
• Extension of drugs’ use – gaining approval for a wider indication range
• Existing products and their futures – leading pharma companies’ strategies
• The race to gain drug approvals, especially from the FDA and EMA
• Progress in clinical trials – finding the most promising medicines
• Patent challenges – protecting intellectual property in a competitive market – the rise of generics and biosimilars
• Combination therapies and other developments for biological drugs
• Cost challenges – pricing and reimbursement, including proving value and clinical superiority.

You also gain SWOT analysis, assessing what drives and restrains that expanding anticancer drugs industry. See what shapes its market from 2016.

Our work shows what is possible for leading pharma companies and specialists in biological drugs and related biotechnologies for combating breast cancer.

【レポートの目次】

1. Report Overview
1.1 Breast Cancer Drugs Overview
1.2 Why you Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by this Report
1.5 Who is this Report for?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQ)
1.8 Some Associated Reports
1.9 About Visiongain

2. Introduction to Breast Cancer and its Treatment
2.1 What is Breast Cancer?
2.2 The Second Most Common Cancer in the World
2.3 Normal Structure of the Human Breast
2.4 Classifying the Different Types of Breast Cancer
2.4.1 Pathology
2.4.2 Molecular Subtype
2.4.3 Stages
2.4.4 Grades
2.5 Treatment Protocols
2.5.1 Treatment Options for Localised Disease
2.5.1.1 The Different Types of Therapy for Localised Breast Cancer
2.5.1.2 Stage 0 – Lobular Carcinoma in Situ (LCIS) and Ductal Carcinoma in Situ (DCIS)
2.5.1.3 Adjuvant Chemotherapy and Adjuvant Hormonal Therapy Treatment Options for Stage 1-3 Localised Disease
2.5.2 Treatment Options for Recurrent or Metastatic Disease

3. Leading Breast Cancer Drugs
3.1 Herceptin (trastuzumab) by Roche: The Leading Breast Cancer Drug
3.1.1 Approved Indications: Breast Cancer is the Main Indication
3.1.2 Roche Builds Franchise of Anti-HER2 mAbs Around Herceptin
3.1.3 Total Herceptin Revenues 2010-2015
3.1.4 The Threat of Biosimilars
3.1.4.1 Hertraz and CanMab (Mylan and Biocon): The First to Win Approval
3.1.4.2 Herzuma (Celltrion)
3.1.4.3 Total Biosimilar Trastuzumab Revenue Forecast, for all Indications, 2016-2026
3.1.5 Herceptin for Breast Cancer Revenue Forecast 2016-2026
3.2 Perjeta (pertuzumab) by Roche
3.2.1 Is a Recent Addition to the Market, Approved for Different Stages of Breast Cancer
3.2.2 Positive Results from Different Clinical Trials
3.2.3 Total Perjeta Revenues 2012-2015
3.2.4 Perjeta for Breast Cancer Revenue Forecast 2016-2026
3.3 Afinitor (everolimus) by Novartis
3.3.1 Multiple Approved Indications but Breast Cancer Leads
3.3.2 No Extension to HER2 Positive Breast Cancer, as Afinitor Fails to Meet Primary Objective in Phase 3 Trial
3.3.3 NICE Rejects Afinitor on Cost Basis, although Drug Remains on the Cancer Drugs Fund, Despite Rumours it Would be Removed
3.3.4 Total Afinitor Revenues 2010-2015
3.3.5 Afinitor for Breast Cancer Revenue Forecast 2016-2026
3.4 Faslodex (fulvestrant) by AstraZeneca
3.4.1 Approved for Breast Cancer all the Way Back in 2002, Higher Dose Approved in 2010
3.4.2 Patent Dispute with Mylan
3.4.3 Total Faslodex Revenues 2010-2015
3.4.4 Faslodex for Breast Cancer Revenue Forecast 2016-2026
3.5 Ibrance (palbociclib) by Pfizer
3.5.1 Accelerated Approval on the Back of Promising Data
3.5.2 Has Already Been Used to Treat Over 15,000 Patients, MAA Filed in Europe
3.5.3 Total Ibrance Revenues Q1-Q4 2015
3.5.4 Ibrance for Breast Cancer Revenue Forecast 2016-2026
3.6 Avastin (bevacizumab) by Roche
3.6.1 Multiple Approved Indications, Still Approved for Breast Cancer in Major Markets, Except for the US
3.6.1.1 Why was the FDA-Breast Cancer Label Withdrawn?
3.6.2 Total Avastin Revenues 2010-2015
3.6.3 Avastin for Breast Cancer Revenue Forecast 2016-2026
3.6.4 No Biosimilars Approved yet, but Multiple Candidates in Clinical Trials
3.6.5 Total Biosimilar Bevacizumab Revenue Forecast, for all Indications, 2016-2026
3.7 Kadcyla (ado-trastuzumab emtansine) by Roche
3.7.1 The First Antibody-Drug Conjugate to be Approved for Breast Cancer
3.7.2 Mixed Results from Different Clinical Trials
3.7.3 Total Kadcyla Revenues 2013-2015
3.7.4 Kadcyla for Breast Cancer Revenue Forecast 2016-2026
3.8 Femara (letrozole) by Novartis
3.8.1 Hormone Therapy for Early Breast Cancer
3.8.2 Total Femara Revenues 2010-2025
3.8.3 Femara for Breast Cancer Revenue Forecast 2016-2026
3.9 Abraxane (paclitaxel Protein-Bound) by Celgene
3.9.1 Breast Cancer was the first of its Approved Indications
3.9.2 Total Abraxane Revenues 2010-2015
3.9.3 Abraxane for Breast Cancer Revenue Forecast 2016-2026

4. Breast Cancer Drugs R&D Pipeline 2016-2026
4.1 Roche: Not Content with Dominating Current Market, Already Grooming Future Leaders
4.1.1 Taselisib (GDC-0032 / RG7604)
4.1.1.1 Positive Results from Phase 1 Trial
4.1.2 Atezolizumab (MPDL3280A / RG7446)
4.1.2.1 Early Results in Triple-Negative Breast Cancer
4.1.3 Investigating Kadcyla and Perjeta in Wider Breast Cancer Indications
4.2 Novartis
4.2.1 Buparlisib (BKM120)
4.2.1.1 Early-Results for Buparlisib in Combination with Olaparib
4.2.2 Alpelisib (BYL719)
4.2.3 Ribociclib (LEE011)
4.2.3.1 Phase 1b Results in Combination with Femara
4.3 AstraZeneca
4.3.1 AZD5363
4.3.1.1 Well Tolerated and Yielding Partial Response in Early Results from 2013
4.3.2 MEDI-573 (In Partnership with MedImmune)
4.4 Abemaciclib (LY2835219) by Eli Lilly
4.4.1 Coveted Breakthrough Therapy Designation from the FDA
4.5 Veliparib (ABT-888) by AbbVie
4.6 Ganetespib by Synta Pharmaceuticals
4.7 Entinostat by Syndax Pharmaceuticals
4.7.1 Syndax Collaborating with Merck and Roche, Breakthrough Therapy Designation
4.8 Lucitanib by Clovis Oncology
4.9 Glembatumumab vedotin (CDX-011) by Celldex Therapeutics
4.9.1 Results from EMERGE Study
4.10 MM-302 by Merrimack
4.10.1 Phase 1 Results Released April 2015
4.11 Neratinib (PB272) by Puma Biotechnology
4.12 ENMD-2076 by CASI Pharmaceuticals
4.13 Margetuximab by MacroGenics

5. Global Breast Cancer Drugs Market 2016-2026
5.1 The Global Breast Cancer Drugs Market Forecast 2016-2026
5.2 What Factors will Drive Growth in the Global Breast Cancer Drugs Market?
5.3 Increasing Rate of Breast Cancer
5.3.1 What Factors are Contributing to this Increase?
5.4 Dynamic and Lucrative Sector with Strong R&D Pipeline
5.5 The Use of Combination Therapies Brings Various Benefits to Both Patients and Companies
5.6 What Factors will Restrain Growth in the Breast Cancer Drugs Market?
5.7 Patent Expiries for Key Drugs Will Open up Market to Generic and Biosimilar Competition
5.8 Declining Healthcare Budgets Lead to Cost Pressures
5.9 New Therapies that Only Offer Modest Benefits over Existing Treatments, and Intense Competition
5.10 SWOT Analysis of the Global Breast Cancer Drugs Market

6. Leading Therapeutic Segments and National Markets within the Global Breast Cancer Drugs Market
6.1 The Main Therapeutic Segments within the Breast Cancer Drugs Market, Forecast 2016-2026
6.1.1 Therapeutic Composition of the Market in 2015, 2020 and 2026
6.1.2 Monoclonal Antibodies (mAbs) Segment Forecast 2016-2026
6.1.3 Chemotherapy and Hormone Therapy Segment
6.1.4 Kinase Inhibitor Segment Forecast 2016-2026
6.1.5 ‘Other’ Segment Forecast 2016-2026
6.2 Leading National Markets for Breast Cancer Drugs
6.2.1 Leading Regional Markets for Breast Cancer, Forecast 2016-2026
6.2.2 Regional Composition of the Market in 2015, 2020 and 2026
6.2.3 US Breast Cancer Drugs Market 2016-2026
6.2.3.1 The Dominant National Market, and will Remain so Throughout the Forecast Period, Although is Undergoing Some Changes
6.2.3.2 US Breast Cancer Drugs Market Forecast 2016-2026
6.2.4 EU5 Breast Cancer Drugs Market 2016-2026
6.2.4.1 German Breast Cancer Drugs Market: The Leading EU Market, Undergoing Reforms
6.2.4.2 German Breast Cancer Drugs Market Forecast 2016-2026
6.2.4.3 French Breast Cancer Drugs Market: Some Reduction in Healthcare Spending, but National Healthcare System Remains Strong
6.2.4.4 French Breast Cancer Drugs Market Forecast 2016-2026
6.2.4.5 Italian Breast Cancer Drugs Market: Facing Challenges
6.2.4.6 Italian Breast Cancer Drugs Market Forecast 2016-2026
6.2.4.7 UK Breast Cancer Drugs Market: Pricing is a Contentious Issue
6.2.4.8 UK Breast Cancer Drugs Market Forecast 2016-2026
6.2.4.9 Spanish Breast Cancer Drugs Market
6.2.4.10 Spanish Breast Cancer Drugs Market Forecast 2016-2026
6.2.5 Japanese Breast Cancer Drugs Market
6.2.5.1 Rapidly Ageing Population will Boost the Market, but will a Successful Generic Market be Established?
6.2.5.2 Japanese Breast Cancer Drugs Market Forecast 2016-2026
6.2.6 BRIC Breast Cancer Drugs Market
6.2.6.1 Chinese Breast Cancer Drugs Market: Nation to Become one of the Major Global Players due to Rapid Growth
6.2.6.2 Chinese Breast Cancer Drugs Market Forecast 2016-2026
6.2.6.3 Brazilian Breast Cancer Drugs Market: Healthcare in the Country is Taking Great Strides Forward
6.2.6.4 Brazilian Breast Cancer Drugs Market Forecast 2016-2026
6.2.6.5 Russian Breast Cancer Drugs Market: Punches Below its Weight
6.2.6.6 Russian Breast Cancer Drugs Market Forecast 2016-2026
6.2.6.7 Indian Breast Cancer Drugs Market: Generics are King
6.2.6.8 Indian Breast Cancer Drugs Market Forecast 2016-2026

7. Research Interviews
7.1 Interview with Dr Ken Ren, CEO of CASI Pharmaceuticals
7.1.1 On ENMD-2076 for Triple Negative Breast Cancer
7.1.2 Status of the Chinese Oncology Market
7.1.3 On the Properties that will Allow CASI to compete Against Giants in the Market, Such as Roche
7.1.4 On Drivers and Restraints for the Market
7.1.5 On the Challenges of Developing a Pipeline Product for the Breast Cancer Market, and Ways of Overcoming Them
7.2 Interview with MacroGenics
7.2.1 On Margetuximab for Metastatic Breast Cancer
7.2.2 On Where Margetuximab would fit into the Competitive HER2 Space
7.2.3 On the Challenges of Developing a Pipeline Product

8. Conclusions from Our Research and Analysis
8.1 How will Revenues Change over the Forecast Period?
8.2 How will the Therapeutic Composition of the Market Change over the Forecast Period?
8.3 How will the Composition of the Global Market Change Over the Forecast Period?
8.4 Concluding Remarks

List of Tables
Table 1.1 Regional Forecasts for the Global Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020: SAMPLE
Table 2.1 Components of the Human Breast
Table 2.2 Classifying Breast Cancer by Pathology
Table 2.3 Different Molecular Subtypes of Breast Cancer
Table 2.4 Staging of Breast Cancer
Table 2.5 The Different Grades of Invasive Breast Cancer
Table 2.6 Key Terms in the Treatment of Early-Stage Breast Cancer
Table 2.7 Management Options for Stage 0 LCIS
Table 3.1 Herceptin Approved Indications and FDA-Approval History
Table 3.2 Total Herceptin Revenues 2010-2015: Revenues ($bn), AGR (%), CAGR (%)
Table 3.3 Biosimilar Trastuzumab Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 3.4 Biosimilar Trastuzumab Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
Table 3.5 Herceptin for Breast Cancer Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 3.6 Herceptin for Breast Cancer Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
Table 3.7 Perjeta Approved Indications and FDA-Approval History
Table 3.8 Total Perjeta Revenues 2012-2015: Revenues ($bn), AGR (%), CAGR (%)
Table 3.9 Perjeta for Breast Cancer Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 3.10 Perjeta for Breast Cancer Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
Table 3.11 Herceptin: Approved Indications and FDA-Approval History
Table 3.12 Total Afinitor Revenues 2010-2015: Revenues ($bn), AGR (%), CAGR (%)
Table 3.13 Afinitor for Breast Cancer Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 3.14 Afinitor for Breast Cancer Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
Table 3.15 Total Faslodex Revenues 2010-2015: Revenues ($bn), AGR (%), CAGR (%)
Table 3.16 Faslodex for Breast Cancer Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 3.17 Faslodex for Breast Cancer Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
Table 3.18 Total Ibrance Revenues Q1 to Q4 2015: Revenues ($bn), Growth Rate (%), Average Growth Rate (%)
Table 3.19 Ibrance for Breast Cancer Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 3.20 Ibrance for Breast Cancer Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),
2021-2026
Table 3.21 Avastin Approved Indications and FDA-Approval History
Table 3.22 Total Avastin Revenues 2010-2015: Revenues ($bn), AGR (%), CAGR (%)
Table 3.23 Avastin for Breast Cancer Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),
2014-2020
Table 3.24 Avastin for Breast Cancer Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),
2021-2026
Table 3.25 Biosimilar Bevacizumab Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 3.26 Biosimilar Bevacizumab Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
Table 3.27 Total Kadcyla Revenues 2013-2015: Revenues ($bn), AGR (%), CAGR (%)
Table 3.28 Kadcyla Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 3.29 Kadcyla Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
Table 3.30 Total Femara Revenues 2010-2015: Revenues ($bn), AGR (%), CAGR (%)
Table 3.31 Femara Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 3.32 Femara Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
Table 3.33 Abraxane Approved Indications and FDA-Approval History
Table 3.34 Total Abraxane Revenues 2010-2015: Revenues ($bn), AGR (%), CAGR (%)
Table 3.35 Abraxane Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 3.36 Abraxane Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
Table 4.1 Taselisib (GDC-0032 / RG7604) Ongoing BC Clinical Trials, 2016
Table 4.2 Atezolizumab (MPDL3280A / RG7446) Ongoing BC Clinical Trials, 2016
Table 4.3 Clinical Investigation of Kadcyla and Perjeta in Wider BC Indications, 2016
Table 4.4 Buparlisib (BKM120) Selected Ongoing and Completed BC Clinical Trials, 2016
Table 4.5 Alpelisib (BYL719) Selected BC Clinical Trials, 2016
Table 4.6 Ribociclib (LEE011) Selected BC Clinical Trials, 2016
Table 4.7 AZD5363: Selected BC Ongoing Clinical Trials, 2016
Table 4.8 Abemaciclib (LY2835219): Selected Ongoing BC Clinical Trials, 2016
Table 4.9 Veliparib (ABT-888): Selected BC Clinical Trials, 2016
Table 4.10 Ganetespib Selected BC Clinical Trials, 2016
Table 4.11 MM-302 BC Clinical Trials, 2016
Table 4.12 Neratinib (PB272) Selected BC Clinical Trials, 2016
Table 4.13 Margetuximab Recent and Ongoing Clinical Trials, 2016
Table 5.1 Global Breast Cancer Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 5.2 Global Breast Cancer Drugs Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2021-2026
Table 6.1 Therapeutic Segments within the Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.2 Therapeutic Segments within the Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.3 mAbs Segment of the Breast Cancer Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.4 mAbs Segment of the Breast Cancer Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.5 Chemotherapy and Hormone Therapy Segment of the Breast Cancer Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.6 Chemotherapy and Hormone Therapy Segment of the Breast Cancer Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.7 Kinase Inhibitor Segment of the Breast Cancer Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.8 Kinase Inhibitor Segment of the Breast Cancer Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.9 ‘Others’ Segment of the Breast Cancer Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.10 ‘Others’ Segment of the Breast Cancer Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.11 Regional Forecasts for the Global Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.12 Regional Forecasts for the Global Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.13 US Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.14 US Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.15 German Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.16 German Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.17 French Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.18 French Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.19 Italian Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.20 Italian Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.21 UK Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.22 UK Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.23 Spanish Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.24 Spanish Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.25 Japanese Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.26 Japanese Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.27 Chinese Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.28 Chinese Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.29 Brazilian Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.30 Brazilian Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.31 Russian Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.32 Russian Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.33 Indian Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.34 Indian Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026

List of Figures
Figure 3.1 Total Herceptin Revenues 2010-2015: Revenues ($bn)
Figure 3.2 Biosimilar Trastuzumab Revenue Forecast: Revenue ($bn), 2014-2026
Figure 3.3 Herceptin for Breast Cancer Revenue Forecast: Revenue ($bn), 2014-2026
Figure 3.4 Total Perjeta Revenues 2012-2015: Revenues ($bn)
Figure 3.5 Perjeta for Breast Cancer Revenue Forecast: Revenue ($bn), 2014-2026
Figure 3.6 Total Afinitor Revenues 2010-2015: Revenues ($bn)
Figure 3.7 Afinitor for Breast Cancer Revenue Forecast: Revenue ($bn), 2014-2026
Figure 3.8 Total Faslodex Revenues 2010-2015: Revenues ($bn)
Figure 3.9 Faslodex for Breast Cancer Revenue Forecast: Revenue ($bn), 2014-2026
Figure 3.10 Total Ibrance Revenues Q1-Q4 2015: Revenues ($bn)
Figure 3.11 Ibrance for Breast Cancer Revenue Forecast: Revenue ($bn), 2015-2026
Figure 3.12 Total Avastin Revenues 2010-2015: Revenues ($bn)
Figure 3.13 Avastin for Breast Cancer Revenue Forecast: Revenue ($bn), 2014-2026
Figure 3.14 Biosimilar Bevacizumab Revenue Forecast: Revenue ($bn), 2014-2026
Figure 3.15 Total Kadcyla Revenues 2013-2015: Revenues ($bn)
Figure 3.16 Kadcyla Revenue Forecast: Revenue ($bn), 2014-2026
Figure 3.17 Total Femara Revenues 2010-2015: Revenues ($bn)
Figure 3.18 Femara Revenue Forecast: Revenue ($bn), 2014-2026
Figure 3.19 Total Abraxane Revenues 2010-2015: Revenues ($bn)
Figure 3.20 Abraxane Revenue Forecast: Revenue ($bn), 2014-2026
Figure 5.1 Global Breast Cancer Drugs Market Forecast: Revenue ($bn), 2014-2026
Figure 5.2 SWOT Analysis of the Global Breast Cancer Drugs Market, 2016
Figure 6.1 Therapeutic Segments within the Breast Cancer Drugs Market: Revenues ($bn), 2014-2026
Figure 6.2 Therapeutic Composition of the Breast Cancer Drugs Market: Market Share (%), 2015
Figure 6.3 Therapeutic Composition of the Breast Cancer Drugs Market: Market Share (%), 2020
Figure 6.4 Therapeutic Composition of the Breast Cancer Drugs Market: Market Share (%), 2026
Figure 6.5 mAbs Segment of the Breast Cancer Market, Forecast: Revenues ($bn), 2014-2026
Figure 6.6 Chemotherapy and Hormone Therapy Segment of the Breast Cancer Market, Forecast: Revenues ($bn), 2014-2026
Figure 6.7 Kinase Inhibitor Segment of the Breast Cancer Market, Forecast: Revenues ($bn),
2014-2026
Figure 6.8 ‘Others’ Segment of the Breast Cancer Market, Forecast: Revenues ($bn), 2014-2026
Figure 6.9 Regional Forecasts for the Global Breast Cancer Drugs Market: Revenues ($bn), 2014-2026
Figure 6.10 Regional Composition of the Global Breast Cancer Drugs Market: Revenues ($bn), Market Share (%), 2015
Figure 6.11 Regional Composition of the Global Breast Cancer Drugs Market: Revenues ($bn), Market Share (%), 2020
Figure 6.12 Regional Composition of the Global Breast Cancer Drugs Market: Revenues ($bn), Market Share (%), 2026
Figure 6.13 US Breast Cancer Drugs Market: Revenues ($bn), 2014-2026
Figure 6.14 German Breast Cancer Drugs Market: Revenues ($bn), 2014-2026
Figure 6.15 French Breast Cancer Drugs Market: Revenues ($bn), 2014-2026
Figure 6.16 Italian Breast Cancer Drugs Market: Revenues ($bn), 2014-2026
Figure 6.17 UK Breast Cancer Drugs Market: Revenues ($bn), 2014-2026
Figure 6.18 Spanish Breast Cancer Drugs Market: Revenues ($bn), 2014-2026
Figure 6.19 Japanese Breast Cancer Drugs Market: Revenues ($bn), 2014-2026
Figure 6.20 Chinese Breast Cancer Drugs Market: Revenues ($bn), 2014-2026
Figure 6.21 Brazilian Breast Cancer Drugs Market: Revenues ($bn), 2014-2026
Figure 6.22 Russian Breast Cancer Drugs Market: Revenues ($bn), 2014-2026
Figure 6.23 Indian Breast Cancer Drugs Market: Revenues ($bn), 2014-2026
Figure 8.1 Global Breast Cancer Drugs Market Forecast: Revenues ($bn), Annual Growth Rate (%), 2014-2026
Figure 8.2 Global Breast Cancer Drugs Market Broken Down by Therapeutic Segment: Revenues ($bn), 2014-2026
Figure 8.3 Leading National Markets for Breast Cancer Drugs: Revenues ($bn), 2015
Figure 8.4 Leading National Markets for Breast Cancer Drugs: Revenues ($bn), 2026

【レポートのキーワード】

乳がん治療薬、モノクローナル抗体、ホルモン、化学療法、キナーゼ阻害剤、医薬品、乳癌薬

★調査レポート[乳がん治療薬の世界市場:モノクローナル抗体、ホルモン、化学療法、キナーゼ阻害剤、その他] (コード:VGAIN6041534)販売に関する免責事項を必ずご確認ください。
★調査レポート[乳がん治療薬の世界市場:モノクローナル抗体、ホルモン、化学療法、キナーゼ阻害剤、その他]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆